Familial Adenomatous Polyposis - Pipeline Insight, 2024

This “Familial Adenomatous Polyposis (FAP)- Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Familial Adenomatous Polyposis (FAP)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Familial Adenomatous Polyposis (FAP) Understanding

Familial Adenomatous Polyposis (FAP): Overview

Familial Adenomatous Polyposis (FAP) is a serious, life-threatening, genetic disorder and is characterized by the initial development of many tens to thousands of adenomas in the rectum and colon during the second decade of life. FAP is caused by a germ line mutation of the adenomatous polyposis coli (APC) gene. The inheritance of FAP is autosomal dominant. FAP causes extra tissue (polyps) to form in large intestine (colon) and rectum. Polyps can also occur in the upper gastrointestinal tract, especially the upper part of small intestine (duodenum). If untreated, the polyps in the colon and rectum are likely to become cancerous.

Symptoms
The symptoms of Familial Adenomatous Polyposis (FAP) include:

• Blood or mucous in the stools
• Changes in bowel habits
• Abdominal pain
• Weight loss

Diagnosis
A diagnosis of Familial Adenomatous Polyposis (FAP) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Screening is done using sigmoidoscopy, colonoscopy, esophagogastroduodenoscopy (EGD) and side-viewing duodenoscopy. CT or MRI imaging of the abdomen and pelvis may be used, especially to evaluate desmoid tumors. Genetic testing can confirm the mutation and disease.

Treatment
Treatment of FAP Patients are managed through regular endoscopic surveillance. Polyps are controlled by polypectomy or ablation. Surgical options include: Colectomy with ileo-rectal anastomosis, Proctocolectomy with ileal pouch anal anastomosis Proctocolectomy with permanent ileostomy. A combination of medications, including nonsteroidal anti-inflammatory drugs, anti-estrogen and chemotherapy is provided for desmoid tumors. Research is continue to evaluate additional treatments for FAP. Medications like sulindac (Clinoril®) and celecoxib (Celebrex®) have been shown to reduce the number of colorectal polyps and delay the timing of the first surgery. These medications can also control polyps in the pouch or rectum after surgery, or the need for additional surgeries.

Familial Adenomatous Polyposis (FAP) Emerging Drugs Chapters

This segment of the Familial Adenomatous Polyposis (FAP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Familial Adenomatous Polyposis (FAP) Emerging Drugs

ALFA: SLA PharmaALFA is an experimental drug that is an arachidonic acid modulators. Alfa is currently in a Phase 3 clinical trial to assess the efficacy and safety of eicosapentaenoic acid free fatty acid (EPA-FFA) for patients with familial adenomatous polyposis (FAP) & ulcerative colitis (UC).

eRapa: Emtora BioscienceseRapa (Sirolimus) is a proprietary, patented, micro-encapsulated formulation of rapamycin that protects the active ingredient from rapid, low pH degradation in the stomach. The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer (Eudragit® L 100 / S 100). eRapa modulates the mTOR pathway, which controls cell growth, proliferation, nutrient transport, autophagy, and survival.

Familial Adenomatous Polyposis (FAP): Therapeutic Assessment

This segment of the report provides insights about the different Familial Adenomatous Polyposis (FAP) drugs segregated based on following parameters that define the scope of the report, such as:

• MajorPlayers in Familial Adenomatous Polyposis (FAP)

There are approx. 12+ key companies which are developing the therapies for Familial Adenomatous Polyposis (FAP). The companies which have their Familial Adenomatous Polyposis (FAP) drug candidates in the most advanced stage, i.e. phase III include, SLA Pharma.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Familial Adenomatous Polyposis (FAP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Familial Adenomatous Polyposis (FAP): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Familial Adenomatous Polyposis (FAP) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Familial Adenomatous Polyposis (FAP) drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Familial Adenomatous Polyposis (FAP) R&D. The therapies under development are focused on novel approaches to treat/improve Familial Adenomatous Polyposis (FAP).
• In August 2019, Emtora Biosciences announced that it will receive a Seed Award grant totaling $3m from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support a Phase 2a trial of the company’s lead drug candidate, eRapaTM, in the treatment of the rare disease Familial Adenomatous Polyposis (FAP).

Familial Adenomatous Polyposis (FAP) Report Insights

• Familial Adenomatous Polyposis (FAP)Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Familial Adenomatous Polyposis (FAP) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Familial Adenomatous Polyposis (FAP) drugs?
• How many Familial Adenomatous Polyposis (FAP) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Familial Adenomatous Polyposis (FAP)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Familial Adenomatous Polyposis (FAP) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Familial Adenomatous Polyposis (FAP) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Emtora Biosciences
• SLA Pharma
• Cancer Prevention Pharmaceuticals
• Janssen Biotech
• Cellix Bio
• Zikani Therapeutics
• TherapyX
• FunPep

Key Products

• eRapa
• ALFA
• Eflornithine/sulindac
• Guselkumab
• Eflornithine/sulindac conjugate
• Ribosomal modulators
• Interleukin 10
• Antibody-inducing peptides

This product will be delivered within 2 business days.